Study on Prognosis of Acute-on-chronic Liver Failure Complicated by Bacterial or Fungal Infection
A Real-world Study on the Long-term Prognosis of Acute-on-chronic Liver Failure
1 other identifier
observational
400
1 country
1
Brief Summary
The subjects of this study were inpatients with ACLF who were admitted to Tongji Hospital in Wuhan from March 2023 to June 2025. After patients were enrolled, The patient's general information (gender, age, past medical history, etc.), complications (ascites, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, etc.), laboratory tests (CRP, PCT, INR, WBC, fungal/bacterial diagnostic tests, etc.), symptoms and signs at the time of infection, and at admission (D1), D4, D7, D14, D21, etc.) were recorded Save the blood separately. The patients were divided into fungal infection group, bacterial infection group and non-infection group according to the infection status after admission.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2023
CompletedFirst Submitted
Initial submission to the registry
May 25, 2024
CompletedFirst Posted
Study publicly available on registry
May 31, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedMay 31, 2024
May 1, 2024
1.8 years
May 25, 2024
May 25, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
incidence rate of bacterial or fungal infection
incidence rate of bacterial or fungal infection
28 days and 90 days
mortality rate of bacterial or fungal infection
mortality rate of bacterial or fungal infection
28 days and 90 days
Secondary Outcomes (1)
incidence rate of complications
28 days and 90 days
Study Arms (3)
non-infection group
patients without bacterial or fungal infection
bacterial infection group
patients with bacterial infection
fungal infection group
patients with fungal infection
Eligibility Criteria
Inpatients with ACLF admitted to Tongji Hospital in Wuhan from March 2023 to June 2025.
You may qualify if:
- TBIL ≥ 12 mg/mL and INR ≥ 1.5
- Chronic hepatitis B
You may not qualify if:
- (1) \<18 or \>80 years old; (2) primary hepatic or extrahepatic carcinoma; (3) with severe diseases of other organs or systems; (4) pregnancy; (5) imcomplete information
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Qin Ninglead
Study Sites (1)
Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 25, 2024
First Posted
May 31, 2024
Study Start
March 1, 2023
Primary Completion
December 31, 2024
Study Completion
June 30, 2025
Last Updated
May 31, 2024
Record last verified: 2024-05